Mycenax Biotech (4726) — Net Asset Momentum
Mycenax Biotech (4726) recorded a net asset momentum of -17.3% as of December 2024, with net assets of NT$2.02 Billion TWD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See 4726 net assets for net asset value and shareholders' equity analysis.
YoY Momentum
Current Net Assets
Years of Data
Country
Mycenax Biotech Net Asset Momentum (2017–2024)
This chart tracks Mycenax Biotech's year-over-year net asset growth across 8 annual reporting periods from 2017 to 2024. The most recent momentum reading is -17.3%, with net assets of NT$2.02 Billion TWD as of December 2024. For live market cap and overall valuation, see 4726 market cap overview.
Annual Net Asset History for Mycenax Biotech (2017–2024)
The table below shows the complete annual net asset history for Mycenax Biotech from 2017 to 2024, covering 8 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check how tangible is Mycenax Biotech's equity to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (TWD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | NT$2.02 Billion | NT$3.37 Billion | NT$1.34 Billion | ▼ -17.3% |
| 2023 | NT$2.45 Billion | NT$3.77 Billion | NT$1.32 Billion | ▼ -21.2% |
| 2022 | NT$3.11 Billion | NT$4.45 Billion | NT$1.35 Billion | ▲ +62.9% |
| 2021 | NT$1.91 Billion | NT$3.14 Billion | NT$1.23 Billion | ▲ +57.4% |
| 2020 | NT$1.21 Billion | NT$1.75 Billion | NT$540.89 Million | ▲ +10.0% |
| 2019 | NT$1.10 Billion | NT$1.41 Billion | NT$306.04 Million | ▲ +21.5% |
| 2018 | NT$907.01 Million | NT$1.12 Billion | NT$211.70 Million | ▼ -20.7% |
| 2017 | NT$1.14 Billion | NT$1.31 Billion | NT$168.93 Million | — |